Warning letter
Vertical Pharmaceuticals, Inc: warning letter of May 10, 2017
FDA warning letter 516774 · New Jersey District Office
Key facts
| Reference number | 516774 |
|---|---|
| Company | Vertical Pharmaceuticals, Inc |
| Subject | Postmarketing Adverse Drug Experience Reporting Requirements |
| Issue date | May 10, 2017 |
| Posted date | May 16, 2017 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| CFR sections cited | 314.80(b), 314.80 |
| Inspection city | Sayreville |
| Inspection ZIP | 08872 |
| Inspection start date | Oct 24, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: